Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy.
Castiglione F, Dell'Oglio P, Tosco L, Everaerts W, Albersen M, Hakim L, Van den Broeck T, Moris L, Claessens F, Briganti A, Montorsi F, Van Poppel H, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Castiglione F, et al. Among authors: moris l. Prostate. 2017 Jan;77(1):3-9. doi: 10.1002/pros.23242. Epub 2016 Aug 16. Prostate. 2017. PMID: 27527377
Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection.
Moris L, Van den Broeck T, Tosco L, Van Baelen A, Gontero P, Karnes RJ, Everaerts W, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Graefen M, Gratzke C, Kneitz B, Marchioro G, Salas RS, Tombal B, Van Der Poel H, Walz JC, De Meerleer G, Bossi A, Haustermans K, Montorsi F, Van Poppel H, Spahn M, Briganti A, Joniau S. Moris L, et al. Front Surg. 2016 Dec 16;3:65. doi: 10.3389/fsurg.2016.00065. eCollection 2016. Front Surg. 2016. PMID: 28018903 Free PMC article.
The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Moris L, Battaglia A, van der Poel H, Walz J, Bossi A, De Meerleer G, Haustermans K, Van Poppel H, Spahn M, Joniau S. Tosco L, et al. Among authors: moris l. Prostate Cancer Prostatic Dis. 2017 Dec;20(4):407-412. doi: 10.1038/pcan.2017.29. Epub 2017 May 9. Prostate Cancer Prostatic Dis. 2017. PMID: 28485390
The role of TET-mediated DNA hydroxymethylation in prostate cancer.
Smeets E, Lynch AG, Prekovic S, Van den Broeck T, Moris L, Helsen C, Joniau S, Claessens F, Massie CE. Smeets E, et al. Among authors: moris l. Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):41-55. doi: 10.1016/j.mce.2017.08.021. Epub 2017 Sep 1. Mol Cell Endocrinol. 2018. PMID: 28870782 Review.
Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer.
Seikkula H, Janssen P, Tutolo M, Tosco L, Battaglia A, Moris L, Van den Broeck T, Albersen M, De Meerleer G, Van Poppel H, Everaerts W, Joniau S. Seikkula H, et al. Among authors: moris l. Front Oncol. 2017 Nov 22;7:280. doi: 10.3389/fonc.2017.00280. eCollection 2017. Front Oncol. 2017. PMID: 29214148 Free PMC article.
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
Tosco L, Laenen A, Gevaert T, Salmon I, Decaestecker C, Davicioni E, Buerki C, Claessens F, Swinnen J, Goffin K, Oyen R, Everaerts W, Moris L, De Meerleer G, Haustermans K, Joniau S; P.E.A.R.L. (ProstatE cAncer Research Leuven). Tosco L, et al. Among authors: moris l. BMC Cancer. 2018 Apr 2;18(1):354. doi: 10.1186/s12885-018-4275-z. BMC Cancer. 2018. PMID: 29606109 Free PMC article.
70 results